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Excessive production of reactive oxygen species (ROS), associated with inflamma-
tion, leads to the condition of oxidative stress. Oxidative stress is a major contributing
factor to the high mortality rates associated with several diseases, including malaria, a
widespread parasitic disease in the tropical parts of the world. It seems that oxidative
stress in malaria plays a dual role. Some authors suggest that oxidative stress seems to
contribute to host organism defenses (1). Namely, immune cells use ROS in order to sup-
port their functions and therefore need adequate levels of antioxidant defenses in order
to avoid the harmful effect of an excessive production of ROS (2). On the other hand,
some authors point to deleterious effects of oxidative stress in malaria (3). In addition,
some antimalarial agents have oxidative stress-inducing effects that might contribute to
the development of side effects such as methemoglobinemia, hemolysis and liver dam-
age (4). Primaquine (PQ) is the only available drug that is active against both the latent
liver forms of relapsing malaria caused by Plasmodium vivax and P. ovale and the gameto-
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cytes from all species of the parasites (5). Modifications of the primary amino group pro-
tect PQ against metabolic degradation and lead to an increase in the antimalarial activity
(6). In our previous paper (7) we have shown that primaquine urea derivatives possess
significant antiradical and antioxidant activities. On the other hand, non-steroidal anti-
-inflammatory drugs (NSAIDs) and their derivatives have also exerted antioxidant ac-
tivities (8). We therefore found it worth preparing a series of PQ-NSAID conjugates, twin
drugs that combine both drugs in a single drug. In this study, novel primaquine conjuga-
tes with ibuprofen, ketoprofen, fenoprofen, diclofenac and indomethacin (PQ-NSAIDs,
4a-h) were prepared, fully chemically characterized and screened for radical scavenging
and antioxidant activity.
A considerable number of iron(III) chelators, as well as certain iron(II) chelators, de-
signed for purposes other than treating malaria have antimalarial activity in vitro (9).
These facts directed us to check a potential of PQ-NSAIDs conjugates as iron chelators.
A series of urea and carbamate PQ derivatives previously synthesized by our group
showed antiproliferative activity (7). On the other hand, NSAIDs are potential antican-
cer drugs and effective chemopreventive agents (see, for example, ref. 10). Therefore,
screening of cytostatic activity on a series of tumour cell lines of PQ-NSAID conjugates
was performed as well.
EXPERIMENTAL
Melting points were determined on a Stuart Melting Point Apparatus SMP3 (Bar-
world Scientific, UK) and were uncorrected. IR spectra were recorded on a FTIR Perkin
Elmer Paragon 500 spectrometer (Perkin Elmer, USA). 1H and 13C NMR spectra were re-
corded on a Varian Gemini 300 spectrometer (Varian, USA), operating at 300 and 75.5
MHz for the 1H and 13C nuclei, respectively. Samples were measured in DMSO-d6 solu-
tions at 20 °C in 5-mm NMR tubes. Chemical shifts (d) in ppm were referred to TMS.
Coupling constants (J) are given in Hz. A Perkin Elmer Lambda 25 spectrophotometer
(Perkin Elmer, USA) and Stat Fax 3200 (Awareness Technologies, USA) were used for
absorbance measurements. Elemental composition of the compounds agreed to within
±0.4 % (CHN-LECO-932, LECO Corporation, USA). For thin-layer chromatography, pre-
coated Merck silica gel 60 F254 plates (Merck, Germany) and solvent systems cyclohex-
ane/ethyl acetate/methanol (3:1:0.5) and dichloromethane/methanol (9:1) were used.
Spots were visualized by short-wave UV light and iodine vapour. Column chromatogra-
phy was performed on silica gel of 0.063–0.200 mm (Merck), with cyclohexane/ethyl ac-
etate/methanol (3:1:0.5) or dichloromethane/methanol (9:1) as eluents. A gradual in-
crease of eluent polarity was also applied: first eluent was lipophylic (dichloromethane),
while the second (dichloromethane/methanol 99.5:0.5) and the third one (dichlorome-
thane/methanol 99:1) were more polar. Benzotriazole, triphosgene, triethylamine, ethy-
lenediamine, primaquine diphosphate, butylated hydroxyanisol (BHA), 2,2-diphenyl-1-
-picrylhydrazyl (DPPH), b-carotene, Folin-Ciocalteu reagent, linoleic acid, Tween-40
(polyoxyethylene sorbitan monopalmitate), quercetin and 10 % Pd/C were purchased
from Sigma-Aldrich (USA). NSAIDs (diclofenac, ketoprofen, fenoprofen, ibuprofen and
indomethacin) were obtained as gift samples from Pliva and Belupo (Croatia) and the
326
Z. Raji} et al.: Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe2+ chelating activity, Acta Pharm. 60
(2010) 325–337.
University of Potchefstroom (Republic of South Africa). Primaquine diphosphate and
NSAIDs were used as racemates. Other chemicals and solvents used were of analytical
grade. 1-Benzotriazole carboxylic acid chloride (1), 2-(3-benzylphenyl)propanoic acid (2a),
2-(3-(hydroxy(phenyl)methyl)phenyl)propanoic acid (2b) and NSAID benzotriazolides
3a-h were prepared according to our published procedures (11, 12). Primaquine base was
prepared from primaquine diphosphate prior to use. Primaquine solution was protected
against light during the whole procedure.
Synthesis of PQ-NSAID twin drugs (4a-h). General procedure
A light-protected solution of primaquine (0.156 g, 0.6 mmol), appropriate benzotria-
zolide 3 (0.5 mmol) and triethylamine (TEA) (0.209 mL, 1.5 mmol) in toluene (5 mL) was
stirred at room temperature for 0.5 h. Synthesis of 4h was performed with a double
amount of primaquine and TEA, while for synthesis of 4g only half the amount of TEA
was used. The reaction mixture was extracted with diluted NaOH solution pH 9 (5 ´ 10
mL). The organic layer was washed with water, dried over anhydrous sodium sulphate,
filtrated and evaporated to yield a crude product.
N-(4-(6-methoxyquinolin-8-ylamino)pentyl)-2-(4-isobutylphenyl)propanamide (4a). – Re-
actant: 1-(1H-benzo[d][1,2,3]triazol-1-yl)-2-(4-isobutylphenyl)propan-1-one (benzotria-
zolide 3a) (0.154 g, 0.5 mmol). The crude product was purified by column chromatogra-
phy (eluent: dichloromethane/methanol 9:1).
N-(4-(6-methoxyquinolin-8-ylamino)pentyl)-2-(3-benzylphenyl)propanamide (4b). – Reac-
tant: 1-(1H-benzo[d][1,2,3]triazol-1-yl)-2-(3-benzylphenyl)propan-1-one (benzotriazolide 3b)
(0.171 g, 0.5 mmol). The crude product was purified by column chromatography (eluent:
cyclohexane/ethyl acetate/methanol 3:1:0.5).
N-(4-(6-methoxyquinolin-8-ylamino)pentyl)-2-(3-phenoxyphenyl)propanamide (4c). – Re-
actant: 1-(1H-benzo[d][1,2,3]triazol-1-yl)-2-(3-phenoxyphenyl)propan-1-one (benzotriazo-
lide 3c) (0.174 g, 0.5 mmol). The crude product was purified by column chromatography
(eluent: cyclohexane/ethyl acetate/methanol 3:1:0.5).
N-(4-(6-methoxyquinolin-8-ylamino)pentyl)-2-(3-benzoylphenyl)propanamide (4d). – Rea-
ctant: 1-(1H-benzo[d][1,2,3]triazol-1-yl)-2-(3-benzoylphenyl)propan-1-one (benzotriazo-
lide 3d) (0.178 g, 0.5 mmol). The crude product was purified by column chromatography
(eluent: cyclohexane/ethyl acetate/methanol 3:1:0.5).
N-(4-(6-methoxyquinolin-8-ylamino)pentyl)-2-(3-(hydroxy(phenyl)methyl)-phenyl)propan
amide (4e). – Reactant: 1-(1H-benzo[d][1,2,3]triazol-1-yl)-2-(3-(hydroxy(phenyl)methyl)
phenyl)propan-1-one (benzotriazolide 3e) (0.179 g, 0.5 mmol). The crude product was
purified by column chromatography (eluent: dichloromethanedichloromethane/me-
thanol 99.5:0.5dichloromethane/methanol 99:1).
2-(2-(2,6-Dichlorophenylamino)phenyl)-N-(4-(6-methoxyquinolin-8-ylamino)pentyl)acet
amide (4f). – Reactant: 2-(2-(2,6-dichlorophenylamino)phenyl)-1-(1H-benzo[d][1,2,3]tria-
zol-1-yl)ethanone (benzotriazolide 3f) (0.199 g, 0.5 mmol). The crude product was puri-
fied by column chromatography (eluent: cyclohexane/ethyl acetate/methanol 3:1:0.5) and
triturated with ether.
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1-(4-Chlorobenzoyl)-2-methyl-5-methoxy-N-(4-(6-methoxyquinolin-8-ylamino)pentyl)-1H-
indol-3-acetamide (4g). – Reactants: 1-(4-chlorobenzoyl)-2-methyl-5-methoxy-1H-indol-3-
-(ethan-2-one-2-(1H-benzo[d][1,2,3]triazol-1-yl)) (benzotriazolide 3g) (0.229 g, 0.5 mmol),
triethylamine (0.091 mL, 0.65 mmol). The crude product was purified by column chro-
matography (eluent: cyclohexane/ethyl acetate/methanol 3:1:0.5) and triturated with
ether.
(3-(1-(4-(6-Methoxyquinolin-8-ylamino)pentylcarbamoyl)ethyl)phenyl)-(phenyl)methyl 4-(6-
methoxyquinolin-8-ylamino)pentylcarbamate (4h). – Reactant: (3-(1-(1H-benzo[d][1,2,3]tria-
zol-1-yl)-1-oxopropan-2-yl)phenyl)(phenyl)methyl 1H-benzo[d][1,2,3]triazole-1-carboxy-
late (benzotriazolide 3h) (0.251 g, 0.5 mmol). The crude product was purified by column
chromatography (eluent: dichloromethane/methanol 9:1) and triturated with acetone/
petrolether.
DPPH radical-scavenging activity
Free radical scavenging activity (RSA) was evaluated by the scavenging of a,a-di-
phenyl-b-picryl hydrazyl (DPPH) radicals according to the method of Yen and Chen
(13). Ethanolic solution of DPPH (V = 1.0 mL, c = 0.16 mmol L–1) was added to 1.0 mL of
either ethanolic solution of the test sample (g = 0.1–0.5 g L–1) or ethanol (negative con-
trol). The mixture was vortexed for 1 min and then left to stand at room temperature in
the dark. After 30 min absorbance was read at 517 nm. Bleached DPPH solution, pre-
pared by adding 1.0 mL of 0.16 mmol L–1 DPPH solution to 1.0 mL of butylated
hydroxyanisol (BHA) solution (g = 1 g L–1) was used as a positive control. RSA was cal-
culated using Acont. (absorbance of the ethanol control) and Asample (absorbance of the
sample). RSAwas expressed as the concentration that scavenges 50 % of DPPH free radi-
cals (EC50).
b-Carotene-linoleic acid assay
The antioxidant activity (ANT) of the selected twin drugs was evaluated using the
b-carotene-linoleic acid system according to modified literature procedures (14). Tween
40 (200 mg) and 1.0 mL of b-carotene solution in chloroform (g = 0.2 mg L–1) were mixed.
After removing chloroform in a rotary evaporator, 20 mg of linoleic acid and 30 mL of
aerated distilled water was added to the oily residue with vigorous stirring. Aliquots
(200 mL) of thus obtained emulsion were added to 50 mg of the test conjugate dissolved
in 50 mL of methanol (final concentration of the test compound 0.2 g L–1). A reaction mix-
ture containing 50 mL of methanol instead of sample solution served as a control. BHA
was used as an antioxidant standard. After adding the emulsion to the tubes, the plate
was incubated at 50 °C for 2 h. During that period, the absorbance was measured at
450 nm at 15-minute intervals, starting immediately after sample preparation (t = 0 min)
until the end of the experiment (t = 120 min).
The percent of antioxidant activity was calculated as described by Al-Saikhan et al.
(15) using Rcont. and Rsample, average bleaching rates of the water control and antioxi-
dant (test compound or BHA), respectively. In addition, antioxidant activity was calcu-
lated from the absolute changes in absorbance at t = 60 and 120 min (AA-60 and AA-120,
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respectively) (14). The results were normalized using two controls: a negative control
with no protection (water) and a positive control with maximum protection (BHA). Ac-
cordingly, the antioxidant activity of the test compounds was expressed as:
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where AEt=0 is the absorbance of the conjugate at 0 min, AEt=t is the absorbance of the
conjugate at t = 60 or 120 min, AWt=0 is the absorbance of the water control at 0 min,
AWt=t is the absorbance of the water control at t = 60 or 120 min, ABHAt=0 is the
absorbance of BHA at 0 min and ABHAt=t is the absorbance of the BHA sample at t = 60
or 120 min.
Fe2+ chelating activity
The chelating activity (ChA) of PQ-NSAID conjugates toward ferrous ions was stud-
ied as described by Decker and Welch with some modification (16). To an aliquot of the
methanolic solution of the test conjugate (V = 150 mL, g = 0.1–0.6 g L–1), 50 mL of FeCl2
solution (c = 0.25 mmol L1) was added. After 5 minutes, the reaction was initiated by
adding 100 mL of 1.0 mmol L–1 ferrozine solution. Absorbance at 545 nm was recorded
after 10 min of incubation at room temperature. A reaction mixture containing 150 mL of
methanol instead of conjugate solution served as a control. Quercetin was used as the
chelating standard. ChA was calculated using Acont. (absorbance of the negative control,
e.g., blank solution without test compound) and Asample (absorbance of the conjugate so-
lution). Chelating activity was expressed as ChEC50, the concentration that chelates 50 %
of Fe2+ ions.
Statistical analysis
All assays described in the paper were performed in triplicate. The results were ex-
pressed as mean ± SD. Statistical comparisons were made using Student’s t-test or
one-way ANOVA, followed by Dunnett’s post-hoc test for multiple comparisons with
the control. Statistical analyses were performed using the JMP V6 from SAS software
(SAS Institute, Cary, NC, USA).
RESULTS AND DISCUSSION
Chemistry
The synthetic procedure leading to PQ-NSAID conjugates 4a-h is presented in the
Scheme 1. The first synthetic step involves preparation of NSAID benzotriazolides 3a-h
from the corresponding NSAID (ibuprofen, ketoprofen, fenoprofen, ketoprofen hydroxy
and methylene analogues, diclofenac or indomethacin) and benzotriazole carboxylic
acid chloride (BtCOCl, 1). Benzotriazolides 3a-h readily reacted with the primaquine
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base. In that reaction, the primaquine terminal amino group formed an amide bond with
the carboxylic group present in the title NSAIDs. The reaction was performed in toluene,
at room temperature for 0.5 h. In general, 3-fold excess of TEA was used. Triethylamine
formed a water soluble salt with benzotriazole, a by-product of the reaction, which was
readily extracted with water. Synthesis of the PQ-indomethacin derivative 4g was per-
formed with benzotriazolide 3g : TEA molar ratio 1 : 1.3 to avoid indomethacin decom-
position. Compound 4h consists of one reduced ketoprofen moiety and two primaquine
units (one bound by an amide and the other by the carbamate bond), and its preparation
required a double amount of primaquine, e.g., PQ to benzotriazolide 3hmolar ratio 2 : 1.
Structures of compounds 4a-h were deduced from the analysis of their IR, 1H and
13C NMR spectra and confirmed by elemental analysis. The chemical shifts were consis-
tent with the proposed structures of the novel compounds. In 1H NMR spectrum of
amidocarbamate derivative 4h each atom of two primaquine residues always appeared
as one signal with a double integral, except for NH group at position 2: carbamate NH
(2’’) appeared at d 7.47–7.39 ppm, while amide NH (2) had a signal at d 7.95–7.91 ppm.
Physicochemical and spectroscopic data are presented in Tables I and II.
Radical scavenging, antioxidant activity and Fe2+ chelating ability
The investigated conjugates demonstrated moderate antiradical activities, with
EC50 between 269.5 ± 10.7 and 379.3 ± 59.1 mg L–1, with the exception of conjugate 4e
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Table I. Physicochemical and IR spectroscopic data for PQ-NSAID conjugates 4a-h
Compd.
Yield
(%)
M.p.
(ºC)
IR (nmax, KBr or NaCl, cm–1)
Molecular
formula (Mr)
Elemental analysis
calcd./found
C H N
4a 98 oil
3384, 3302, 3052, 2957, 2930, 1868,
1645, 1616, 1577, 1520, 1456, 1387,
1220, 1203, 1166, 1052, 822, 791
C28H37N3O2
(447.61)
75.13
75.49
8.33
8.40
9.39
9.20
4b 98 oil
3386, 3301, 3060, 3027, 2965, 2930,
1647, 1616, 1577, 1520, 1455, 1388,
1220, 1202, 1167, 1159, 822, 791
C31H35N3O2
(481.63)
77.31
77.48
7.32
7.44
8.72
8.60
4c 97 oil
3385, 3300, 3069, 2964, 2931, 1646,
1616, 1581, 1520, 1488, 1456, 1388,
1245, 1222, 1206, 1161, 1051, 932,
821, 791, 693
C30H33N3O3
(483.60)
74.51
74.39
6.88
6.71
8.69
8.95
4d 95 34–38
3380, 3310, 3059, 2965, 2932, 1655,
1616, 1596, 1578, 1520, 1455, 1388,
1284, 1221, 1202, 1159, 1052, 822,
791, 722, 705
C31H33N3O3
(495.61)
75.13
75.40
6.71
6.58
8.48
8.66
4e 85 oil
3391, 3310, 3061, 2965, 1932, 2870,
1650, 1616, 1578, 1520, 1454, 1388,
1221, 1202, 1159, 823, 791, 703
C31H35N3O3
(497.63)
74.82
74.98
7.09
7.39
8.44
8.22
4f 90 128–130
3393, 3298, 3070, 2964, 2941, 1661,
1633, 1616, 1591, 1578, 1521, 1454,
1389, 1205, 1158, 820, 768, 752
C29H30Cl2N4O2
(536.17)
64.80
64.46
5.63
5.68
10.42
10.07
4g 77 113–116
3383, 3302, 3083, 2960, 2929, 1669,
1641, 1617, 1596, 1520, 1478, 1458,
1388, 1364, 1332, 1222, 1154, 1090,
823, 792, 754
C34H35ClN4O4
(599.12)
68.16
67.83
5.89
5.70
9.35
9.20
4h 93 82–86
3384, 3055, 2962, 2932, 1716, 1660,
1616, 1588, 1520, 1455, 1424, 1388,
1238, 1221, 1203, 1159, 1051, 1031,
822, 792
C47H54N6O5
(782.97)
72.10
72.44
6.95
7.09
10.73
10.35
4b 4d 4e 4f 4h4gBHA
0
0.2
0.4
0.6
0.8
E
C
(g
L
)
50
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1
Fig. 1. DPPH radical scavenging activi-
ties of the PQ-NSAID conjugates and
butylated hydroxyanisol (BHA). Mean
± SD, n = 3.
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Table II. 1H and 13C NMR data for PQ-NSAID conjugates 4a-h
Compd. R
1H NMR (DMSO-d6, d/ppm, J/Hz)
13C NMR (DMSO-d6, d/ppm)
4a
8.53 (d, 1H, 17, J = 3.79), 8.07 (dd, 1H, 15, J = 1.61, J = 6.65),
7.92–7.87 (m, 1H, 2), 7.42 (dd, 1H, 16, J = 3.96, J = 4.30), 7.19
(dd, 2H, 4’, 8’, J = 1.81, J = 6.25), 7.02 (dd, 2H, 5’, 7’, J = 2.02,
J = 6.25), 6.47 (d, 1H, 10, J = 2.42), 6.25 (d, 1H, 12, J = 1.61), 6.07
(dd, 1H, 8, J = 2.42, J = 6.25), 3.82 (s, 3H, 18), 3.60–3.48 (m, 2H,
6, 1’), 2.96–2.87 (m, 2H, 3), 2.35 (d, 2H, 9’, J = 6.65), 1.82–1.69
(m, 1H, 10’), 1.60–1.38 (m, 4H, 4, 5), 1.28 (dd, 3H, 2’, J = 3.02,
J = 3.83), 1.14 (dd, 3H, 7, J = 2.22, J = 3.93), 0.82 (d, 6H, 11’,
12’, J = 6.45)
173.68 (1), 159.49 (11), 145.09 (9), 144.67 (17), 140.15, 139.55 (3’,
6’), 135.25 (15), 135.01 (14), 130.05 (13), 129.15, 127.34 (4’, 8’, 5’,
7’), 122.55 (16), 96.55 (10), 92.06 (12), 55.44 (18), 47.43 (6), 45.26
(1’), 44.69 (9’), 38.91 (3), 33.77 (5), 30.06 (10’), 26.36 (4), 22.61
(11’, 12’), 20.61 (7), 18.84 (2’)
4b
8.53 (dd, 1H, 17, J = 1.55, J = 2.62), 8.08 (dd, 1H, 15, J = 1.54,
J = 6.73), 7.91 (t, 1H, 2, J = 5.32), 7.44–7.40 (m, 1H, 16), 7.28–7.01
(m, 9H, 4’–6’, 8’, 11’–15’), 6.48 (d, 1H, 10, J = 2.53), 6.25 (s, 1H,
12), 6.09 (dd, 1H, 8, J = 1.61, J = 7.01), 3.88 (s, 2H, 9’), 3.82 (s,
3H, 18), 3.45–3.34 (m, 2H, 6, 1’), 2.95–2.87 (m, 2H, 3), 1.61–1.40
(m, 4H, 4, 5), 1.28 (dd, 3H, 2’, J = 3.52), 1.14 (dd, 3H, 7, J = 1.55,
J = 4.58)
173.47 (1), 159.49 (11), 145.09 (9), 144.69 (17), 143.03, 141.64,
141.43 (3’, 7’, 10’), 135.26 (15), 135.01 (14), 130.05 (13), 129.09,
128.82, 128.69, 128.08, 127.26, 126.37, 125.30 (4’–6’, 8’, 11’–15’),
122.57 (16), 96.59 (10), 92.07 (12), 55.45 (18), 47.36 (6), 45.57 (1’),
41.63 (9’), 38.98 (3), 33.79 (4), 26.37 (5), 20.63 (7), 18.99 (2’)
4c
8.53 (dd, 1H, J = 1.51, 17, J = 2.65), 8.08 (dd, 1H, 15, J = 1.51,
J = 6.81), 7.96 (t, 1H, 2, J = 5.39), 7.44–6.82 (m, 10H, 16, 4’–6’, 8’,
10’–14’), 6.48 (d, 1H, 10, J = 2.44), 6.26 (s, 1H, 12), 6.09 (dd, 1H,
8, J = 1.75, J = 6.90), 3.82 (s, 3H, 18), 3.61–3.52 (m, 2H, 6, 1’),
3.08–3.00 (m, 2H, 3), 1.62–1.39 (m, 4H, 4, 5), 1.29 (dd, 3H, 2’,
J = 3.50), 1.15 (dd, 3H, 7, J = 1.06, J = 4.94)
173.18 (1), 159.48 (11), 157.05, 156.89 (3’, 7’, 9’), 145.09 (9), 144.70
(17), 135.26 (15), 135.01 (14), 130.05 (13), 122.56 (16), 130.44, 130.15,
123.79, 122.79, 118.96, 117.99, 116.99 (4’–6’, 8’, 10’–14’), 96.58 (10),
92.08 (12), 55.44 (18), 47.35 (6), 45.44 (1’), 39.01 (3), 33.84 (4), 26.37
(5), 20.63 (7), 18.85 (2’)
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4d
8.52 (d, 1H, 17, J = 4.18), 8.07 (dd, 1H, 15, J = 1.53, J = 6.64),
8.04 (t, 1H, 2, J = 5.49, 2), 7.72–7.46 (m, 9H, 4’–6’, 8’, 11’–15’),
7.41 (dd, 1H, 16, J = 4.09, J = 4.18), 6.47 (d, 1H, 10, J = 2.17),
6.24 (t, 1H, 12, J = 2.63), 6.08 (dd, 1H, 8, J = 4.03, J = 4.61), 3.82
(d, 3H, 18, J = 2.02), 3.68 (q, 1H, 1’, J = 7.03), 3.61–3.54 (m, 1H,
6), 3.10–3.00 (m, 2H, 3), 1.62–1.41 (m, 4H, 4, 5), 1.34 (t, 3H, 2’,
J = 6.78), 1.14 (dd, 3H, 7, J = 5.76, J = 6.20)
196.16 (9’), 173.16 (1), 159.47 (11), 145.08 (9), 144.68 (17), 143.33,
137.51, 137.29 (3’, 7’, 10’), 135.25 (15), 135.00 (14, 13), 133.09,
132.04, 130.05, 128.99, 128.94, 128.50 (4’–6’, 8’, 11’–15’), 122.55
(16), 96.56 (10), 92.07 (12), 55.44 (18), 47.35 (6), 45.39 (1’), 38.94
(3), 33.84 (4), 26.31 (5), 20.63 (7), 18.87 (2’)
4e
8.53 (d, 1H, 17, J = 4.13), 8.08 (dd, 1H, 15, J = 1.45, J = 6.77),
7.93–7.91 (m, 1H, 2), 7.42 (dd, 1H, 16 J = 4.05, J = 4.20),
7.35–7.13 (m, 9H, 4’–6’, 8’, 12’–16’), 6.48 (d, 1H, 10, J = 2.42),
6.26 (t, 1H, 12, J = 2.20), 6.09 (dd, 1H, 8, J = 3.13, J = 5.44), 5.85
(d, 1H, 10’, J = 3.91), 5.65–5.64 (m, 1H, 9’), 3.82 (s, 3H, 18),
3.61–3.56 (m, 1H, 6), 3.53 (q, 1H, 1’, J = 7.16), 3.08–2.95 (m, 2H,
3), 1.61–1.58, 1.52–1.41 (2m, 4H, 4, 5), 1.29–1.26 (m, 3H, 2’),
1.17–1.14 (m, 3H, 7)
173.47 (1), 159.49 (11), 146.12, 145.98, 142.66 (3’, 7’, 10’), 145.11
(9), 144.71 (17), 135.27 (15), 135.02 (14), 130.06 (13), 128.46,
128.30, 127.10, 126.69, 126.03, 125.60, 124.89 (4’–6’, 8’, 12’–16’),
122.57 (16), 96.60 (10), 92.11 (12), 74.82 (9’), 55.46 (18), 47.46 (6),
45.64 (1’), 39.03 (3), 33.83 (4), 26.33 (5), 20.64 (7), 19.06 (2’)
4f
8.53 (dd, 1H, 17, J = 1.56, J = 2.66, 17), 8.41 (s, 1H, 8’), 8.36 (t,
1H, 2, J = 5.42), 8.07 (dd, 1H, 15, J = 1.52, J = 6.79), 7.50 (d, 2H,
11’, 13’, J = 8.08), 7.42 (dd, 1H, 16, J = 4.14), 7.20–7.12 (m, 2H,
3’, 5’), 7.05–7.00 (m, 1H, 12’), 6.85–6.80 (m, 1H, 4’), 6.47 (d, 1H,
10, J = 2.41), 6.30–6.27 (m, 2H, 12, 6’), 6.12 (d, 1H, 8, J = 8.80),
3.82 (s, 3H, 18), 3.67–3.56 (m, 1H, 6), 3.56 (s, 2H, 1’), 3.15–3.07
(m, 2H, 3), 1.69–1.49 (m, 4H, 4, 5), 1.17 (d, 3H, 7, J = 6.42)
171.89 (1), 159.49 (11), 145.12 (9), 144.69 (17), 143.42, 137.66,
129.84, 126.05 (2’, 7’, 9’, 10’, 14’), 135.26 (15), 135.01 (14), 130.05
(13), 122.55 (16), 130.80, 129.63, 127.60, 125.41, 121.10, 116.40
(3’–6’, 11’–13’), 96.59 (10), 92.08 (12), 55.45 (18), 47.42 (6), 40.07
(1’), 39.18 (3), 33.83 (4), 26.24 (5), 20.68 (7)
4g
8.52 (dd, 1H, 17, J = 1.52, J = 2.64), 8.07 (dd, 1H, 15, J = 1.45,
J = 6.86), 8.04 (t, 1H, 2, J = 5.59), 7.65 (q, 4H, 12’, 16’, 13’, 15’,
J = 8.64,), 7.42 (dd, 1H, 16, J = 4.03, J = 4.21), 7.11 (d, 1H, 5’,
J = 2.38), 6.94 (d, 1H, 6’, J = 8.97), 6.69 (dd, 1H, 8’, J = 2.44,
J = 6.60), 6.47 (d, 1H, 10, J = 2.38), 6.25 (d, 1H, 12, J = 2.38),
6.10 (d, 1H, 8, J = 8.71), 3.81 (s, 3H, 18), 3.72 (s, 3H, 2’’),
3.65–3.56 (m, 1H, 6), 3.48 (s, 2H, 1’), 3.12–3.05 (m, 2H, 3), 2.21
(s, 3H, 1’’), 1.66–1.46 (m, 4H, 4, 5), 1.16 (d, 3H, 7, J = 6.20)
169.66 (1), 168.29 (10’), 159.47 (11), 156.00 (7’), 145.09 (9), 144.69
(17), 137.98 (14’), 135.53 (3’), 135.26 (15), 135.00 (14), 134.74 (4’),
131.58 (12’, 16’), 131.35 (11’), 130.75 (9’), 130.04 (13), 129.47 (13’,
15’), 122.57 (16), 115.01 (5’), 114.92 (2’), 111.67 (6’), 102.34 (8’),
96.57 (10), 92.07 (12), 55.83 (2’’), 55.44 (18),47.46 (6), 39.14 (3),
33.93 (4), 31.70 (1’), 26.50 (5), 20.63 (7), 13.82 (1’’)
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'
14'
CH3
15'
O
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'
14'
15'
CH3OH
16'
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'
14'
Cl
Cl
H
N
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'
14'
15'
N
O
H3C
O Cl
CH3
1''
2''
16'
with EC50 = 528.8 mg L–1. BHA, investigated under the same conditions, had the EC50
value of 5.9 mg L–1. The results are presented in Fig. 1.
Reduction of the absorbance of the b-carotene-linoleate emulsion in the presence of
PQ-NSAID conjugates is shown in Fig. 2. All the investigated derivatives significantly
inhibited b-carotene bleaching in comparison with the control. According to Amarowicz
et al. (17), the normalized antioxidant activity at 60 and 120 min of incubation (AA-60
and AA-120) probably reflects the antioxidant activity of the test compound more accu-
rately than the ANT value (Table III). Differences among the PQ-NSAID conjugates were
minor. The most active conjugate, according both to the ANT value (69.4 ± 0.9 %) or
AA-60 (58.4 ± 3.1 %) and AA-120 (59.3 ± 1.8 %), was conjugate 4h with two primaquine
units. The activity of diclofenac derivative 4f was the lowest; however, activities of both
4h and 4f were not statistically different from the activity of the other conjugates.
Small differences in antioxidant, as well as in antiradical activities, could indicate
that the primaquine moiety, which all the investigated substances have in common,
might be responsible for both activities.
Under the conditions applied in our experiments only ketoprofen derivatives 4d
and 4e demonstrated chelating activities with ChEC50 of 1074.7 ± 23.2 and 861.9 ± 50.4
mg L–1, respectively. ChEC50 of standard quercetin was 537.6 ± 13.5 mg L–1. Other more
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4h
8.53 (d, 2H, 17, 17’’, J = 3.67), 8.07 (dd, 2H, 15, 15’’, J = 0.97,
J = 7.15), 7.95–7.91 (m, 1H, 2), 7.47–7.39 (m, 3H, 16, 2’’, 16’’),
7.30–7.17 (m, 9H, 4’–6’, 8’, 11’–15’), 6.62 (s, 1H, 9’), 6.47 (d, 2H,
10, 10’’, J = 1.31), 6.25 (s, 2H, 12, 12’’), 6.10 (t, 2H, 8, 8’’, J =
8.28), 3.81 (s, 6H, 18, 18’’), 3.64–3.50 (m, 3H, 6, 1’, 6’’), 3.07–2.95
(m, 4H, 3, 3’’), 1.65–1.39 (m, 8H, 4, 5, 4’’, 5’’), 1.27 (dd, 3H, 2’,
J = 2.28, J = 3.63), 1.18–1.11 (m, 6H, 7, 7’’)
173.31 (1), 159.48 (11), 155.79 (11’), 145.10 (9, 9’’), 144.69 (17,
17’’), 143.02, 141.76, 141.57 (3’, 7’, 10’), 135.25 (15, 15’’), 135.02
(14, 14’’), 130.05 (13, 13’’), 128.80, 127.92, 126.99, 126.95, 125.94,
125.10 (4’–6’, 8’, 11’–15’), 122.56 (16, 16’’), 96.58 (10, 10’’), 92.07
(112, 12’’), 76.53 (9’), 55.44 (18, 18’’), 47.44 (6, 6’’), 45.54 (1’),
39.02 (3, 3’’), 33.77 (4, 4’’), 26.70 (5), 26.30 (5’’), 20.62 (7, 7’’),
19.02 (2’)
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Fig. 2. Reduction of absorbance in the
b-carotene-linoleate assay in the pres-
ence of the PQ-NSAID conjugates and
butylated hydroxyanisol (BHA). Mean
± SD, n = 3.
lipophilic derivatives precipitated upon addition of aqueous reagent solutions, so it was
not possible to determine their chelating abilities.
Antiproliferative and antituberculotic activity
Antiproliferative activity of PQ-NSAID conjugates was screened in vitro on 4 hu-
man cell lines, which are derived from 4 cancer types. The following cell lines were
used: HCT 116 (colon carcinoma), SW 620 (colon carcinoma), MCF-7 (breast carcinoma),
and H 460 (lung carcinoma). Unfortunately, activities of all conjugates were too weak
(concentration that causes 50 % growth inhibition was  100 µmol L–1). Preliminary anti-
tuberculotic activity was checked as well. The minimal inhibitory concentration deter-
mined on the strain Mycobacterium smegmatis ATCC 14468 was too high ( 128 mg L–1),
so no further tests were done.
CONCLUSIONS
All the tested PQ-NSAID conjugates were found to possess moderate antiradical
acivity, with EC50 between 269.5 ± 10.7 and 379.3 ± 59.1 mg L–1, with the exception of
conjugate 4e with EC50 = 528.8 mg L–1. Conjugate 4h exerted the strongest antioxidant
activity, as determined by the b-carotene-linoleic acid assay (ANT = 69.4 ± 0.9 %; AA-60
and AA-120 were approximately 59 %). Moreover, primaquine derivatives with the keto-
profen moiety demonstrated notable Fe2+ chelating ability. On the other hand, negligible
antiproliferative and antituberculotic effects of conjugates 4a-h were observed. Screen-
ing of antimalarial activity is in progress and the results will be published elsewhere.
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Table III. Antioxidant activity in the -carotene-linoleate assay (ANT, AA-60, AA-120) and metal
chelating activity (ChEC50) of PQ-NSAID conjugates
Compd. ANT (%)a AA-60 (%)a AA-120 (%)a ChEC50 (mg L1)b
4b 60.8 ± 1.8c,d,e 44.8 ± 8.2c 48.1 ± 5.2c,d ND
4d 6 3.2 ± 1.8c,f,g 50.2 ± 8.9c 50.5 ± 2.3c 1074.7 ± 23.2c,d
4e 62.8 ± 1.7c,h,i 49.1 ± 5.9c 52.0 ± 3.4c 861.9 ± 50.4c,d
4f 55.8 ± 1.7c,d,f,h,j,k 39.8 ± 4.9c,d 44.5 ± 3.1c,e ND
4g 61.4 ± 2.3c,j,l 46.6 ± 6.3c 50.1 ± 4.0c ND
4h 69.4 ± 0.9c,e,g,i,k,l 58.4 ± 3.1c,d 59.3 ± 1.8c,d,e ND
Standarda,b 96.6 ± 1.1 95.7 ± 5.2 95.0 ± 3.3 537.6 ± 13.5
ND - activity could not be determined due to precipitation.
ANT – Antioxidant activity relative to water control (determined at test compounds concentration of 0.2 g L–1).
AA-60 and AA-120 – absolute changes in absorbance at t = 60 and 120 min (compounds concentration of 0.2 g L–1).
Standards: a BHA (0.2 g L–1), b quercetin.
Statistically significant difference (p < 0.05) within columns: c vs. standard, d–l between test compounds (the
same letter indicates significant difference).
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Acronyms. – AA-60 and AA-120 – absolute changes in absorbance at t = 60 and 120
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zotriazolyl; ChA – metal chelating activity; ChEC50 – concentration that chelates 50 % of
Fe2+ ions); DPPH – a,a-diphenyl-b-picryl hydrazyl; EC50 – concentration that scavenges
50 % of DPPH free radicals; NSAID – non-steroidal anti-inflammatory drug; PQ – pri-
maquine; ROS – reactive oxygen species; RSA – radical scavenging activity; TEA – tri-
ethylamine.
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S A @ E T A K
Dvojni lijekovi primakina i nesteroidnih protuupalnih lijekova: Sinteza, hvatanje
slobodnih radikala, antioksidativno djelovanje i keliranje Fe2+ iona
ZRINKA RAJI], MARIJANA ZOVKO KON^I], KRISTINA MILOLO@A, IVANA PERKOVI],
IVAN BUTULA, FRANZ BUCAR i BRANKA ZORC
U radu je opisana sinteza novih konjugata primakina s nesteroidnim protuupalnim
lijekovima (PQ-NSAIDs, 4a-h), njihova potpuna karakterizacija te testiranje sposobnosti
hvatanja slobodnih radikala i antioksidativnog djelovanja. Sintetski postupak za pripra-
vu dvojnih lijekova 4a-h uklju~uje dva koraka: i) pripravu NSAID-benzotriazolida 3a-h
iz odgovaraju}ih nesteroidnih protuupalnih lijekova (ibuprofena, ketoprofena, fenopro-
fena, hidroksi i metilenskih analoga ketoprofena, diklofenaka i indometacina) i klorida
1-benzotriazol karboksilne kiseline (BtCOCl, 1), ii) reakciju intermedijera 3a-h s prima-
kinom. Novi PQ-NSAID konjugati pokazuju umjerenu sposobnost hvatanja slobodnih
radikala u DPPH testu te umjereno antioksidativno djelovanje u pokusu s b-karotenom i
linoleinskom kiselinom. Osim toga, derivati ketoprofena 4d i 4b imaju primjetnu spo-
sobnost keliranja Fe2+ iona. Svi konjugati 4a-h pokazuju vrlo slabo antiproliferativno i
antituberkulotsko djelovanje.
Klju~ne rije~i: primakin, NSAID, dvojni lijek, konjugat, hvatanje slobodnih radikala, antioksidativno
djelovanje, sposobnost keliranja
Farmaceutsko-biokemijski fakultet Sveu~ili{ta u Zagrebu, Zagreb, Hrvatska
Institut für Pharmazeutische Wissenschaften, Bereich Pharmakognosie, Graz, Austria
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